INSTITUT PASTEUR

Interleukin-2 variants with modified biological activity

N° AU2025204934A1

Immunogenic product comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL 13 expression or activity

N° AU2025204082A1

VARIANTS OF TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE AND USES THEREOF

N° US2025223575A1

RIPK3-INDUCED CELL DEATH OF MALIGNANT B CELLS

N° WO2025163184A1

RAVIDASVIR, VELPATASVIR, AND ELBASVIR FOR BLOCKING TRANSMISSION OF PLASMODIUM GAMETOCYTES

N° WO2025162911A1

Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers

N° IL318598A

LENTIVIRAL VECTORS FOR EXPRESSION OF HUMAN PAPILLOMAVIRUS (HPV) ANTIGENS AND ITS IMPLEMENTATION IN THE TREATMENT OF HPV INDUCED CANCERS

N° MX2025000929A

BROADLY SARS-COV-2 NEUTRALIZING MONOCLONAL ANTIBODIES AND USES THEREOF

N° WO2025153707A1

IMMUNOCYTOKINE FOR CANCER TREATMENT

N° WO2025133175A1

NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

N° US2025090657A1

NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

N° US2025090656A1

AAV MEDIATED GENE THERAPY THAT RESTORES OTOFERLIN GENE

N° JP2025032155A

METHODS AND REAGENTS FOR DETECTING PIPERAQUINE-RESISTANT PLASMODIUM FALCIPARUM MALARIA

N° US2025092471A1

ENGINEERED PHAGEMIDS AND METHODS FOR ANTIBACTERIAL PEPTIDE DELIVERY AGAINST BACTERIAL PATHOGENS IN PARTICULAR CLOSTRIDIOIDES DIFFICILE

N° WO2025109112A1

Nucleic acid vaccine against the SARS-CoV-2 coronavirus

N° US2025057942A1

METHOD FOR VISUALIZING AT LEAST A ZONE OF AN OBJECT IN AT LEAST ONE INTERFACE

N° US2025014299A1

ANTIBODIES DIRECTED TO ACE2 AND THEIR USE AS MEDICINE

N° WO2025056771A1

NOVEL NANOPARTICLES OF ANTIRETROVIRAL DRUGS, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS

N° US2024398981A1

ANELLOVIRUS GENOME QUANTIFICATION AS A BIOMARKER OF IMMUNE SUPPRESSION

N° US2024368713A1

IMMUNOGENIC PRODUCT COMPRISING IL-4 AND/OR IL-13 FOR TREATING DISORDERS ASSOCIATED WITH ABERRANT IL-4 AND/OR IL 13 EXPRESSION OR ACTIVITY

N° US2025025541A1

MICROFLUIDIC DEVICE FOR STUDYING AND/OR MANIPULATING A STUDY MEDIUM AND/OR AT LEAST ONE MICRO-OBJECT

N° WO2025012418A1

SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST HUMAN TRANSMEMBRANE- SERINE PROTEASE 2 (TMPRSS2)

N° WO2024252183A1

HETERODIMER OF POXVIRUS A16 AND G9 PROTEINS AS AN IMMUNOGEN

N° WO2024236192A1

TUMOR SPECIFIC ANTIGENS AND USES THEREOF

N° WO2024231420A1

Optimized vector for delivery in microbial populations

N° IL312476A

RECOMBINANT PROTEIN, EXPRESSION CASSETTE, IMMUNOGENIC COMPOSITION AND USE THEREOF

N° WO2024227236A1

METHOD FOR IDENTIFYING ABNORMALITIES IN CELLS OF INTEREST IN A BIOLOGICAL SAMPLE

N° WO2024231061A1

Variants of terminal deoxynucleotidyl transferase and uses thereof

N° US2024254459A1

COMBINED ANTIBODIES AGAINST SARBECOVIRUSES AND USES THEREOF

N° WO2024209076A1

ADENO-ASSOCIATED VIRUS VECTOR ENCODING CONNEXIN 26 AND USES THEREOF

N° WO2024200790A1

Nucleic acid vaccine against the SARS-CoV-2 coronavirus

N° US2024252622A1

ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOF

N° US2024270790A1

ANTIBODIES AGAINST ORTHOHANTAVIRUSES

N° WO2024192280A2

Dual recombinant aav8 vector system encoding isoform 5 of otoferlin and uses thereof

N° IL311345A

OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS

N° US2024218380A1

BACTERIOPHAGE THERAPY

N° US2024342230A1

IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS

N° US2024197923A1

Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof

N° US12281155B1

BROADLY SARS-COV-2 NEUTRALIZING MONOCLONAL ANTIBODIES AND USES THEREOF

N° WO2025153835A1

POTENTIATION OF AMINOGLYCOSIDES THROUGH ACTIVATION OF CARBOHYDRATE TRANSPORTERS

N° WO2024149894A1

Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity

N° IL309932A

Variants of a DNA polymerase of the polX family

N° AU2023282219A1

ANTI-DENGUE VACCINES AND ANTIBODIES

N° JP2024037829A

DIPEPTIDYLPEPTIDASE 4 INHIBITION ENHANCES LYMPHOCYTE TRAFFICKING, IMPROVING BOTH NATURALLY OCCURRING TUMOR IMMUNITY AND IMMUNOTHERAPY

N° US2024100048A1

VARIANTS OF A DNA POLYMERASE OF THE POLX FAMILY

N° US2024124855A1

LASSA VACCINE

N° JP2024009058A

GENERATION OF ANTIBODIES ACTING AS SILENT AND POSITIVE ALLOSTERIC MODULATORS OF THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR

N° WO2024100448A1

POLYNUCLEOTIDES AND LENTIVIRAL VECTORS EXPRESSING NON-STRUCTURAL ANTIGENS OF A FLAVIVIRUS SELECTED FROM THE GROUP OF DENV, ZIKV AND YFV, INDUCING PROTECTIVE CD8+ T-CELL IMMUNITY IN A HOST

N° WO2024084041A2

IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS

N° JP2024009933A

LENTIVIRAL VECTOR, LENTIVIRAL PARTICLE FOR TREATING HEPATITIS B AND ITS PREPARATION METHOD AND APPLICATION THEREOF

N° ZA202309368B

Acidic exopolysaccharides with immune activation activity

N° CN120051573A

ACIDIC BACTERIAL EXOPOLYSACCHARIDE HAVING IMMUNOPOTENTIATING ACTIVITY

N° WO2024071336A1

ACIDIC BACTERIAL EXOPOLYSACCHARIDE HAVING IMMUNOPOTENTIATING ACTIVITY

N° EP4596703A1

ACIDIC BACTERIAL EXOPOLYSACCHARIDE HAVING IMMUNOPOTENTIATING ACTIVITY

N° AU2023352000A1

Nucleic acid vaccine against the SARS-CoV-2 coronavirus

N° US2024024462A1

Nucleic acid vaccine against the SARS-CoV-2 coronavirus

N° US2024042014A1

A METHOD FOR IDENTIFYING GENOMIC INTERACTIONS

N° WO2025056933A1

PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES

N° US2024002423A1

ANTIBODIES THAT POTENTLY NEUTRALIZE RABIES VIRUS AND OTHER LYSSAVIRUSES AND USES THEREOF

N° US2024050565A1

METHODS AND SYSTEMS FOR GENERATING NUCLEIC ACID DIVERSITY IN CRISPR-ASSOCIATED GENES

N° WO2024038003A1

METHODS AND SYSTEMS FOR GENERATING NUCLEIC ACID DIVERSITY IN CRISPR-ASSOCIATED GENES

N° EP4573197A1

HSC70-4 IN HOST-INDUCED AND SPRAY-INDUCED GENE SILENCING

N° EP4562168A1

HSC70-4 IN HOST-INDUCED AND SPRAY-INDUCED GENE SILENCING

N° WO2024023578A1

LENTIVIRAL VECTORS FOR EXPRESSION OF HUMAN PAPILLOMAVIRUS (HPV) ANTIGENS AND ITS IMPLEMENTATION IN THE TREATMENT OF HPV INDUCED CANCERS

N° WO2024023135A1

LENTIVIRAL VECTORS FOR EXPRESSION OF HUMAN PAPILLOMAVIRUS (HPV) ANTIGENS AND ITS IMPLEMENTATION IN THE TREATMENT OF HPV INDUCED CANCERS

N° AU2023316754A1

LENTIVIRAL VECTORS FOR EXPRESSION OF HUMAN PAPILLOMAVIRUS (HPV) ANTIGENS AND ITS IMPLEMENTATION IN THE TREATMENT OF HPV INDUCED CANCERS

N° EP4561619A1

Lentiviral vectors for expressing human papilloma virus (HPV) antigens and their use in treatment of HPV-induced cancers

N° CN119894530A

인간 유두종 바이러스(HPV) 항원 발현을 위한 렌티바이러스 벡터 및 HPV 유도 암 치료로의 구현

N° KR20250043538A

USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES

N° US2023357435A1

BACTERIOPHAGE(S) TARGETING CAPSULAR DEFICIENT KLEBSIELLA PNEUMONIAE (KP), COMPOSITIONS COMPRISING IT(THEM) AND USE(S) THEREOF

N° WO2024013350A1

BACTERIOPHAGE(S) TARGETING CAPSULAR DEFICIENT KLEBSIELLA PNEUMONIAE (KP), COMPOSITIONS COMPRISING IT(THEM) AND USE(S) THEREOF

N° EP4555073A1

BENZAMIDE ADENINE DINUCLEOSIDE COMPOUNDS AND THEIR USES

N° WO2024013349A1

Dispositif microfluidique d’étude et/ou de manipulation d’un milieu d’étude et/ou d’un moins un micro-objet.

N° FR3150967A1

Measles-hiv or measles-htlv vaccine

N° IL304441A

Nucleic acid vaccine against the SARS-CoV-2 coronavirus

N° US2024000922A1

METHOD FOR DETECTING HPV INFECTION IN NON-EROSIVE LICHEN PLANUS

N° WO2024013120A2

METHOD FOR DETECTING HPV INFECTION IN NON-EROSIVE LICHEN PLANUS

N° EP4551938A2

ANTI-CNG REPEATS ANTIBODIES AND THEIR DIAGNOSIS APPLICATIONS

N° WO2023247766A1

IMMUNOGENIC PRODUCTS COMPRISING IL-4 AND/OR IL-13 FOR TREATING DISEASES ASSOCIATED WITH ABERRANT EXPRESSION OR ACTIVITY OF IL-4 AND/OR IL-13

N° JP2023110045A

알츠하이머병 및 노화의 치료 및 예방을 위한 라크노스피라세에 종 및 루미노코커스 락타리스 균주

N° KR20250025362A

LACHNOSPIRACEAE SPP AND RUMINOCOCCUS LACTARIS STRAINS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND AGING

N° EP4525897A1

STRAIN OF STRAIN OF STRAIN OF STRAIN OF STRAIN OF STRAIN OF STRAIN OF STRAIN OF STRAIN OF

N° CN119546318A

LACHNOSPIRACEAE SPP AND RUMINOCOCCUS LACTARIS STRAINS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND AGING

N° WO2023222924A1

IDENTIFYING THE MINIMAL CATALYTIC CORE OF DNA POLYMERASE D AND APPLICATIONS THEREOF

N° EP4526438A1

IDENTIFYING THE MINIMAL CATALYTIC CORE OF DNA POLYMERASE D AND APPLICATIONS THEREOF

N° WO2023222863A1

IDENTIFICATION OF A HUMAN CIRCOVIRUS

N° EP4526478A1

인간 시르코바이러스의 확인

N° KR20250075537A

IDENTIFICATION OF A HUMAN CIRCOVIRUS

N° WO2023223092A1

Identification of human circovirus

N° CN119585444A

RECOMBINANT MEASLES VIRUS EXPRESSING ZIKA VIRUS PROTEINS AND APPLICATIONS THEREOF

N° JP2023107780A

METHOD FOR IDENTIFYING ABNORMALITIES IN CELLS OF INTEREST IN A BIOLOGICAL SAMPLE

N° US2024378720A1

HUMAN INNATE LYMPHOID CELL PRECURSORS: IDENTIFICATION, CHARACTERIZATION, APPLICATIONS

N° US2023323304A1

METHOD FOR IDENTIFYING ABNORMALITIES IN CELLS OF INTEREST IN A BIOLOGICAL SAMPLE

N° EP4462380A1

METHOD FOR THE SELECTION OF LYMPHOCYTES

N° EP4519688A1

PREVENTION AND/OR TREATMENT OF HEARING LOSS OR IMPAIRMENT

N° US2023405085A1

FC-ENGINEERED ANTI-HUMAN IGE ANTIBODIES AND METHODS OF USE

N° US2024076410A1

COMBINED ANTIBODIES AGAINST SARBECOVIRUSES AND USES THEREOF

N° EP4442276A1

OXO-AZAHETEROCYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF MALARIA

N° WO2023194411A1

Immunotherapy targeting neoantigen peptides derived from tumor transposon elements in glioblastoma

N° CN119816320A

MULTIVALENT MOPEVAC-BASED IMMUNOGENIC COMPOSITION FOR VACCINATION AGAINST NEW WORLD ARENAVIRUSES AND THERAPEUTIC USE(S) THEREOF

N° WO2023175044A1